Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Eliem Therapeutics reports Q1 EPS (50c), consensus (56c) » 06:12
05/16/22
05/16
06:12
05/16/22
06:12
ELYM

Eliem Therapeutics

$4.41 /

+0.43 (+10.80%)

Cash, cash equivalents…

Cash, cash equivalents and short- and long-term marketable securities was $149.9M as of March 31, 2022, as compared to $47.9M as of March 31, 2021. This includes net proceeds from the company's August 2021 initial public offering. The company's current cash, cash equivalents and short- and long-term marketable securities are expected to fund operations through at least 2023. "We are excited about the potential of our pipeline in multiple neuronal excitability disorders," said Bob Azelby, president and CEO officer of Eliem Therapeutics. "While disappointed by the negative outcome of ETX-810 in diabetic peripheral neuropathic pain, we look forward to providing the topline Phase 2a data for ETX-810 in lumbosacral radicular pain, the chronic pain indication with the most robust precedent clinical validation for this mechanism, in the third quarter of 2022. In addition to ETX-810, we remain committed to the development of our ETX-155 program in depression and epilepsy and will provide an update on our path forward once we complete our previously reported root cause analysis relating to the interim results from our Phase 1b photosensitive epilepsy trial. Due to our strong balance sheet, we also intend to advance our novel Kv7 channel opener program into IND-enabling studies this year and we continue to believe this program has potential to be best-in-class."

ShowHide Related Items >><<
ELYM Eliem Therapeutics
$4.41 /

+0.43 (+10.80%)

ELYM Eliem Therapeutics
$4.41 /

+0.43 (+10.80%)

04/26/22 Guggenheim
Eliem Therapeutics downgraded yesterday at Guggenheim after study failure
04/25/22 Guggenheim
Eliem Therapeutics downgraded to Neutral from Buy at Guggenheim
01/18/22 Stifel
Eliem Therapeutics timing updates don't impact thesis, says Stifel
09/08/21 Evercore ISI
Eliem Therapeutics initiated with an Outperform at Evercore ISI
ELYM Eliem Therapeutics
$4.41 /

+0.43 (+10.80%)

  • 10
    Aug
Downgrade
Eliem Therapeutics downgraded yesterday at Guggenheim after study failure » 07:53
04/26/22
04/26
07:53
04/26/22
07:53
ELYM

Eliem Therapeutics

$2.88 /

-3.63 (-55.76%)

As previously reported…

As previously reported yesterday, Guggenheim analyst Yatin Suneja downgraded Eliem Therapeutics to Neutral from Buy and removed the firm's price target after the company announced the ETX-810 Phase 2a study in diabetic peripheral neuropathic pain, or DPNP, failed to meet its primary endpoint at week 4. The company also has elected to delay enrollment in the Phase 2a studies for ETX-155 in MDD and PMD following an analysis from three patients in the Phase Ib PSE study indicating that drug levels were significantly lower than expected, noted Suneja, who is moving to the sidelines until there is more clarity from the company regarding the ETX-155 issues and updated trial timelines.

ShowHide Related Items >><<
ELYM Eliem Therapeutics
$2.88 /

-3.63 (-55.76%)

ELYM Eliem Therapeutics
$2.88 /

-3.63 (-55.76%)

04/25/22 Guggenheim
Eliem Therapeutics downgraded to Neutral from Buy at Guggenheim
01/18/22 Stifel
Eliem Therapeutics timing updates don't impact thesis, says Stifel
09/08/21 Evercore ISI
Eliem Therapeutics initiated with an Outperform at Evercore ISI
09/07/21 SVB Leerink
SVB Leerink bullish on Eliem Therapeutics, initiates with an Outperform
ELYM Eliem Therapeutics
$2.88 /

-3.63 (-55.76%)

  • 10
    Aug
Downgrade
Eliem Therapeutics downgraded to Neutral from Buy at Guggenheim » 14:07
04/25/22
04/25
14:07
04/25/22
14:07
ELYM

Eliem Therapeutics

$2.90 /

-3.61 (-55.45%)

Guggenheim analyst Yatin…

Guggenheim analyst Yatin Suneja downgraded Eliem Therapeutics to Neutral from Buy.

ShowHide Related Items >><<
ELYM Eliem Therapeutics
$2.90 /

-3.61 (-55.45%)

ELYM Eliem Therapeutics
$2.90 /

-3.61 (-55.45%)

01/18/22 Stifel
Eliem Therapeutics timing updates don't impact thesis, says Stifel
09/08/21 Evercore ISI
Eliem Therapeutics initiated with an Outperform at Evercore ISI
09/07/21 SVB Leerink
SVB Leerink bullish on Eliem Therapeutics, initiates with an Outperform
09/07/21 SVB Leerink
Eliem Therapeutics initiated with an Outperform at SVB Leerink
ELYM Eliem Therapeutics
$2.90 /

-3.61 (-55.45%)

  • 10
    Aug
Hot Stocks
Eliem Therapeutics provides update on ETX-155 program, delays enrollment » 07:52
04/25/22
04/25
07:52
04/25/22
07:52
ELYM

Eliem Therapeutics

$6.50 /

-0.305 (-4.48%)

Eliem Therapeutics…

Eliem Therapeutics provided an update on the status of the ETX-155 clinical program in epilepsy and depression. ETX-155 is in an ongoing Phase 1b proof-of-concept trial in photosensitive epilepsy. Eliem has reviewed interim results from the Phase 1b PSE study and has elected to delay enrollment of its Phase 2a clinical trials of ETX-155 in major depressive disorder and perimenopausal depression. Three patients have been evaluated to date in the Phase 1b PSE study, and the results of ETX-155 on the photoparoxysmal response observed following intermittent photic stimuli were inconclusive. An analysis of the drug exposures in these patients indicated that drug levels were significantly lower than expected based on the pharmacokinetic profile observed in the two Phase 1 trials of ETX-155 in healthy subjects. The company is currently investigating potential root causes of the observed difference in exposure from the prior studies, including evaluation of any differences between the lots of drug product used in this study and those of the prior Phase 1 trials. The company will provide an update to timelines after the root cause is further investigated. "Given the inconclusive results in the Phase 1b PSE study, which appear to be related to lower-than-expected drug exposure, we are focused on ensuring that we understand the reason for these reduced exposures before advancing into the larger Phase 2a trials in MDD and PMD," said Valerie Morisset, executive vice president and chief scientific officer of Eliem Therapeutics. "ETX-155 has demonstrated an encouraging pharmacokinetic, tolerability and safety profile in Phase 1 trials in healthy subjects, as well as promising preclinical activity in anxiety, depression, and seizure models. We remain optimistic about the potential opportunity for ETX-155 in depression and seizure disorders, and we anticipate progressing our Phase 2 trials as soon as practicable." Bob Azelby added, "We continue to be excited about the potential of our pipeline of drug candidates in multiple neuronal excitability disorders, and we are well capitalized to fund the company through multiple additional catalysts across the pipeline. Next quarter, we anticipate the read out of the topline Phase 2a data for ETX-810 in LSRP, the chronic pain indication with the most robust precedent clinical validation for this mechanism. In addition to mapping out the path forward for our ETX-155 program in depression and epilepsy, we also expect to progress our novel Kv7 channel opener program into IND-enabling studies this year. We believe our Kv7 channel opener program has potential to be best-in-class, with the opportunity to evaluate in multiple indications across epilepsy, depression, and pain."

ShowHide Related Items >><<
ELYM Eliem Therapeutics
$6.50 /

-0.305 (-4.48%)

ELYM Eliem Therapeutics
$6.50 /

-0.305 (-4.48%)

01/18/22 Stifel
Eliem Therapeutics timing updates don't impact thesis, says Stifel
09/08/21 Evercore ISI
Eliem Therapeutics initiated with an Outperform at Evercore ISI
09/07/21 SVB Leerink
SVB Leerink bullish on Eliem Therapeutics, initiates with an Outperform
09/07/21 SVB Leerink
Eliem Therapeutics initiated with an Outperform at SVB Leerink
ELYM Eliem Therapeutics
$6.50 /

-0.305 (-4.48%)

  • 10
    Aug
Hot Stocks
Eliem announces Phase 2a trial of ETX-810 did not achieve primary endpoint » 07:52
04/25/22
04/25
07:52
04/25/22
07:52
ELYM

Eliem Therapeutics

$6.50 /

-0.305 (-4.48%)

Eliem Therapeutics…

Eliem Therapeutics reported results from its Phase 2a clinical trial investigating ETX-810 for the treatment of diabetic peripheral neuropathic pain, DPNP. Update on ETX-810: In the Phase 2a clinical trial in DPNP, ETX-810 did not achieve statistically significant separation from placebo on the trial's primary endpoint, which assessed the change from baseline to week 4 in the weekly average of the daily pain score measured with the Pain Intensity Numerical Rating Scale. "We are obviously disappointed with the results of this proof-of-concept trial of ETX-810," said Bob Azelby, president and chief executive officer of Eliem. "Given the positive precedent clinical data for ETX-810's mechanism of action in multiple neuropathic pain populations, it is unfortunate that we were unable to confirm a benefit in the DPNP patients studied in this trial. We believe all aspects of this trial were well-executed, with appropriate patient selection, well-balanced study arms, and placebo effect in-line with expectations, so we are confident that the results are unambiguous and that there is not currently a development path forward in DPNP for ETX-810. We sincerely thank the patients who participated in this trial, along with the investigators, clinical staff, and Eliem team who managed the study. We look forward to seeing the results of our LSRP trial in the third quarter." The multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluated the efficacy and safety of ETX-810 in 159 subjects with DPNP over four weeks of dosing. 78 patients received 1,000 mg of ETX-810 twice daily, and 81 patients received placebo. ETX-810 was well tolerated in the study, with an encouraging safety profile. However, the primary endpoint of the study was not achieved, and separation from placebo on the PI-NRS was not observed during the 4 weeks of dosing. The company has also fully enrolled its Phase 2a proof-of-concept trial evaluating ETX-810 in patients with LSRP. The LSRP study has enrolled 149 patients and has a similar design to the Phase 2a DPNP study. The LSRP study is expected to report topline data in the third quarter of 2022.

ShowHide Related Items >><<
ELYM Eliem Therapeutics
$6.50 /

-0.305 (-4.48%)

ELYM Eliem Therapeutics
$6.50 /

-0.305 (-4.48%)

01/18/22 Stifel
Eliem Therapeutics timing updates don't impact thesis, says Stifel
09/08/21 Evercore ISI
Eliem Therapeutics initiated with an Outperform at Evercore ISI
09/07/21 SVB Leerink
SVB Leerink bullish on Eliem Therapeutics, initiates with an Outperform
09/07/21 SVB Leerink
Eliem Therapeutics initiated with an Outperform at SVB Leerink
ELYM Eliem Therapeutics
$6.50 /

-0.305 (-4.48%)

  • 10
    Aug
Over a month ago
Hot Stocks
Eliem Therapeutics appoints Susan Franks as SVP, head of regulatory affairs » 07:02
04/05/22
04/05
07:02
04/05/22
07:02
ELYM

Eliem Therapeutics

$8.34 /

+0.045 (+0.54%)

Eliem Therapeutics…

Eliem Therapeutics announced the strengthening of its executive team with the appointment of Susan Franks, MS as Eliem's Senior Vice President and Head of Regulatory Affairs. Franks most recently served as the Senior Vice President and Head of Regulatory Affairs at Braeburn Inc., where she was responsible for managing the regulatory team with a focus on its opioid use disorder and pain pipeline.

ShowHide Related Items >><<
ELYM Eliem Therapeutics
$8.34 /

+0.045 (+0.54%)

ELYM Eliem Therapeutics
$8.34 /

+0.045 (+0.54%)

01/18/22 Stifel
Eliem Therapeutics timing updates don't impact thesis, says Stifel
09/08/21 Evercore ISI
Eliem Therapeutics initiated with an Outperform at Evercore ISI
09/07/21 SVB Leerink
SVB Leerink bullish on Eliem Therapeutics, initiates with an Outperform
09/07/21 SVB Leerink
Eliem Therapeutics initiated with an Outperform at SVB Leerink
ELYM Eliem Therapeutics
$8.34 /

+0.045 (+0.54%)

  • 10
    Aug
Earnings
Eliem Therapeutics reports Q4 EPS (40c), consensus (62c) » 16:30
03/07/22
03/07
16:30
03/07/22
16:30
ELYM

Eliem Therapeutics

$9.49 /

+0.4 (+4.40%)

Cash, cash equivalents…

Cash, cash equivalents and marketable securities was $161.4M as of December 31, 2021, as compared to $20.5M as of December 30, 2020. This includes net proceeds from the company's August 2021 initial public offering. The company's current cash, cash equivalents and marketable securities are expected to fund operations through late 2023. "In 2021, we made significant progress on our pipeline and raised sufficient capital to fund the company through multiple catalysts," said Bob Azelby, president and chief executive officer of Eliem Therapeutics. "We were excited to start off the new year by completing our Phase 2a clinical trial of ETX-810 in diabetic peripheral neuropathic pain and look forward to presenting the topline data from this trial in the first half of this year. Even with a polypharmacy approach, a majority of patients with chronic pain are unable to achieve clinically significant reductions in pain and are often balancing tolerability tradeoffs to achieve additional pain reduction. With ETX-810, we believe we have the potential to introduce a differentiated chronic pain therapy that is both efficacious and well-tolerated. On our ETX-155 program, we expect to report interim data on our proof-of-concept Phase 1b study for photosensitive epilepsy, and we look forward to dosing patients in our depression studies assuming FDA clearance of our IND."

ShowHide Related Items >><<
ELYM Eliem Therapeutics
$9.49 /

+0.4 (+4.40%)

ELYM Eliem Therapeutics
$9.49 /

+0.4 (+4.40%)

01/18/22 Stifel
Eliem Therapeutics timing updates don't impact thesis, says Stifel
09/08/21 Evercore ISI
Eliem Therapeutics initiated with an Outperform at Evercore ISI
09/07/21 SVB Leerink
SVB Leerink bullish on Eliem Therapeutics, initiates with an Outperform
09/07/21 SVB Leerink
Eliem Therapeutics initiated with an Outperform at SVB Leerink
ELYM Eliem Therapeutics
$9.49 /

+0.4 (+4.40%)

  • 10
    Aug
Over a quarter ago
Conference/Events
Eliem Therapeutics to hold a virtual investor event » 10:25
02/16/22
02/16
10:25
02/16/22
10:25
ELYM

Eliem Therapeutics

$9.18 /

+0.18 (+2.00%)

Virtual Investor Event…

Virtual Investor Event featuring opinion leaders in chronic pain research to be held on February 16 at 10:30 am. Webcast Link

ShowHide Related Items >><<
ELYM Eliem Therapeutics
$9.18 /

+0.18 (+2.00%)

ELYM Eliem Therapeutics
$9.18 /

+0.18 (+2.00%)

01/18/22 Stifel
Eliem Therapeutics timing updates don't impact thesis, says Stifel
09/08/21 Evercore ISI
Eliem Therapeutics initiated with an Outperform at Evercore ISI
09/07/21 SVB Leerink
SVB Leerink bullish on Eliem Therapeutics, initiates with an Outperform
09/07/21 SVB Leerink
Eliem Therapeutics initiated with an Outperform at SVB Leerink
ELYM Eliem Therapeutics
$9.18 /

+0.18 (+2.00%)

  • 10
    Aug
ELYM Eliem Therapeutics
$9.18 /

+0.18 (+2.00%)

Conference/Events
Eliem Therapeutics to hold a virtual investor event » 09:34
02/16/22
02/16
09:34
02/16/22
09:34
ELYM

Eliem Therapeutics

$9.18 /

+1.17 (+14.61%)

Virtual Investor Event…

Virtual Investor Event featuring opinion leaders in chronic pain research to be held on February 16 at 10:30 am. Webcast Link

ShowHide Related Items >><<
ELYM Eliem Therapeutics
$9.18 /

+1.17 (+14.61%)

ELYM Eliem Therapeutics
$9.18 /

+1.17 (+14.61%)

01/18/22 Stifel
Eliem Therapeutics timing updates don't impact thesis, says Stifel
09/08/21 Evercore ISI
Eliem Therapeutics initiated with an Outperform at Evercore ISI
09/07/21 SVB Leerink
SVB Leerink bullish on Eliem Therapeutics, initiates with an Outperform
09/07/21 SVB Leerink
Eliem Therapeutics initiated with an Outperform at SVB Leerink
ELYM Eliem Therapeutics
$9.18 /

+1.17 (+14.61%)

  • 10
    Aug
ELYM Eliem Therapeutics
$9.18 /

+1.17 (+14.61%)

Conference/Events
Eliem Therapeutics participates in a conference call with Stifel » 13:25
01/24/22
01/24
13:25
01/24/22
13:25
ELYM

Eliem Therapeutics

$8.82 /

-1.7 (-16.16%)

Biotech Analyst Matteis…

Biotech Analyst Matteis holds a conference call with management on January 24 at 2 pm hosted by Stifel.

ShowHide Related Items >><<
ELYM Eliem Therapeutics
$8.82 /

-1.7 (-16.16%)

ELYM Eliem Therapeutics
$8.82 /

-1.7 (-16.16%)

01/18/22 Stifel
Eliem Therapeutics timing updates don't impact thesis, says Stifel
09/08/21 Evercore ISI
Eliem Therapeutics initiated with an Outperform at Evercore ISI
09/07/21 SVB Leerink
SVB Leerink bullish on Eliem Therapeutics, initiates with an Outperform
09/07/21 SVB Leerink
Eliem Therapeutics initiated with an Outperform at SVB Leerink
ELYM Eliem Therapeutics
$8.82 /

-1.7 (-16.16%)

  • 10
    Aug
ELYM Eliem Therapeutics
$8.82 /

-1.7 (-16.16%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.